Trial Profile
A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related Overgrowth
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Taselisib (Primary)
- Indications Growth disorders
- Focus Adverse reactions
- Acronyms TOTEM
- 07 Nov 2019 Status changed from recruiting to discontinued.
- 25 Sep 2017 New trial record